Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Biosimilars / GBMA Position on Biosimilars / Pharmacy Substitution

Pharmacy Substitution

‘a’ flagging is a well-established mechanism that is well understood by physicians and pharmacists

  • The PBAC has stated it will determine “a” flagging on a case-by-case basis. PBAC is an independent expert committee appointed by the Australian Government. Members include eminent, highly qualified and experienced physicians, health professionals, health economists and consumer representatives. Its decisions are based on evidence about clinical effectiveness, safety and cost-effectiveness.
  • A recent study shows that the “no brand substitution” box is ticked on only a very small number of prescriptions – 1% of computer-generated prescriptions and 0.7% of handwritten prescriptions. [Ref Newby DA, Robertson J. Computerised prescribing: assessing the impact on prescription repeats and on generic substitution of some commonly used antibiotics. MJA 2010; 192: 192-195].
  • Pharmacists are required by law to follow the instructions of the prescribing physician on a prescription. Under section 103 of the National Health Act 1953 it is illegal for substitution to occur when the script is marked “no brand substitution permitted”. The offence carries a penalty of $2000 or imprisonment for 12 months, or both.
  • The PSA Guidelines for Pharmacists on PBS Brand Substitution state clearly that brand substitution may only occur after consultation with and agreement of the patient (or the carer), and if the prescriber has not indicated on the prescription, “no substitution”, or equivalent. Pharmacists are also directed specifically to be consistent in the selection of brands for patients on long-term therapy, in order to avoid confusion.

A PBAC recommendation for ‘a’ flagging should be made where supporting evidence exists

  • Substitution is recommended by the PBAC only after the TGA has determined that a medicine is comparable to the reference medicine. Both determinations are reliant on government authorities evaluating data and providing a recommendation on whether the biosimilar is similar enough to the biologic so that approval of the product with reduced clinical and preclinical data can take place. If not, they would ask for it or reject the application.
  • Current reporting has not identified a different rate or type of adverse event (AE) being reported for biosimilars, even though there is heightened awareness of the potential and hence potentially increased reporting of AEs. The risk of new, serious adverse events for registered biosimilars is much lower than for new or modified biologics.
  • GBMA supports robust and adequate pharmacovigilance for all medicinal products based on their individual risk profile, regardless of whether the product is a reference or a follow-on product, a chemical molecule or a biologic. Due to the special characteristics of biologics (certain variability due to batch-to-batch variation or manufacturing changes), it is especially important for biologics that adverse event reporting does not solely rely on the International Non-proprietary Name (INN), but also uses available differentiators like brand name, company name, and batch number.
  • Biosimilars should be required to adhere to appropriate risk management plans comparable to those required for other biologics in the same class. There is no rationale to hold them to a higher standard.

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us